Fig. 1.

Decisions about enrolment into trials based on clinical assessment of disease activity

Patients were divided based on clinical assessment of disease activity by two physicians into three subgroups: active symptoms, clinical remission or uncertain clinical assessment, which included non-specific constitutional symptoms alone and symptoms that could be interpreted as active disease or damage. Both physicians independently rated whether each patient would fulfill the enrolment criteria for the AGATA trial. Both raters agreed to enrol all patients with active symptoms, agreed not to enrol all patients in clinical remission and disagreed about whether to enrol a subset of patients with uncertain clinical assessment. AGATA: A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Takayasu Arteritis.